Peptide Reconstitution: A Bench Method for Lyophilised Research Peptides
A bench method for reconstituting lyophilised peptides: equilibration, diluent choice, adding diluent, concentration tables, aliquoting and labelling.
By the APL Research Team · Updated · First published · 8 min read
Reconstitution turns a freeze-dried cake into the solution every later measurement depends on, and most of its failure modes are invisible: moisture drawn in when a cold vial is opened, peptide stuck to the walls, foam at the air–water interface, or an arithmetic slip that propagates into every dilution. This guide sets out a bench method for lyophilised research peptides, the reasoning behind each step, and the concentration maths. It is written for in-vitro work: biochemical assays, cell culture and analytical standards.
What a good reconstitution achieves
Every step below serves one or more of four outcomes:
- Complete dissolution: no film, gel or particles left on the glass.
- A known concentration: in mass and molar units, corrected for net peptide content where the work needs it.
- No added contamination: microbial, particulate or chemical.
- Minimal loss: to surfaces, interfaces and degradation before the solution is used or frozen.
Before the vial is opened
Bring it to room temperature sealed
A vial straight from the freezer is colder than the dew point of laboratory air, so opening it immediately condenses water onto the glass and the powder. Dried peptides take up that water readily, and water content matters: in lyophilised insulin held at elevated temperature, the extent of aggregation tracked the water taken up by the powder [1]. Leave the vial sealed on the bench, or in a desiccator, until it is at room temperature; around 20–30 minutes suits a small vial.
Collect the powder
Lyophilised cakes fracture in transit, and fragments end up on the stopper or in the neck. Tap the vial gently on the bench, or give it a brief low-speed spin in a centrifuge fitted for vials, so all the powder sits at the bottom before any liquid goes in.
Read the batch documentation
Note the molecular weight, the salt form, any stated net peptide content and any recommended solvent before choosing a diluent. For cell-based work the counter-ion deserves attention: trifluoroacetate at 10⁻⁸ to 10⁻⁷ M reduced proliferation of cultured osteoblasts and chondrocytes, and the TFA salts of three peptides suppressed proliferation more than their hydrochloride salts [2]. Understanding certificates of analysis and TFA vs acetate peptide salts explain what to look for. For our vials, batch documentation is available on request.
Look at the cake
A normal cake is white to off-white, porous and either intact or broken into dry fragments. Shrinkage, a glassy collapsed layer, stickiness or discolouration points to moisture or heat exposure and is worth recording before going further; the peptide storage guide covers causes. Slow wetting on its own is not a defect: in lyophilised protein formulations, amorphous cakes can resist liquid penetration and float, dissolving by gradual surface erosion [3].
Choosing the diluent
Choose the solvent from the sequence and the downstream assay rather than by habit. The net charge at neutral pH and the isoelectric point predict most outcomes.
| Peptide property | First choice | If that fails | Notes |
|---|---|---|---|
| Net positive charge at pH 7 (Lys/Arg-rich) | Sterile water | Small volume of dilute acetic acid, then water to volume | Selank (net +2) falls here |
| Net negative charge at pH 7 (Asp/Glu-rich) | Sterile water or neutral buffer | Dilute ammonium bicarbonate | BPC-157 (pI near 3.8) and Epithalon fall here |
| Rich in hydrophobic residues, little net charge | Minimal DMSO, then aqueous diluent added slowly | DMF; acetonitrile for analytical work only | Keep the final organic fraction low in cell assays |
| Contains Cys, Met or Trp | Degassed water or buffer | Avoid DMSO for free-Cys peptides | Oxidation-prone residues |
| Stock for cell-based assays, single use | Sterile water | Sterile low-strength buffer | Nothing extra enters the vehicle |
| Stock entered repeatedly for biochemical work | Bacteriostatic water | Sterile water in aliquots | Benzyl alcohol becomes part of the vehicle |
Acidifying a basic peptide does more than dissolve it. With the decapeptide cetrorelix, acetic acid reduced adsorption to vial surfaces by giving the molecules a repulsive charge, and in such media the HPLC response rose up to five-fold [4]. Dissolve in water first and add buffer concentrate afterwards; salts can lower the solubility of some sequences. When the first solvent fails, follow the escalation in peptide solubility troubleshooting, and for the preservative question see bacteriostatic water vs sterile water.
Adding the diluent
- Wipe the septum with 70% alcohol and let it dry completely. The full aseptic routine is in sterile technique for peptide handling.
- Measure the diluent with a calibrated pipette in a clean air cabinet, or with a sterile syringe and needle through the septum.
- Run the liquid slowly down the inside wall of the vial, not onto the cake.
- Swirl gently or roll the vial between the fingers, let it stand for a few minutes, and repeat. Do not vortex or shake.
- If a film or particles remain after 10–15 minutes, stop and diagnose rather than escalating the agitation.
The reason for gentleness is often misstated. Bench-scale shear does not break peptide bonds: concentrated antibody solutions exposed to shear rates of up to 250,000 s⁻¹ did not aggregate from shear alone, and the authors calculated that forces at an air–water interface far exceed those of shear [5]. Interfaces are the problem. For the GLP-1 analogue liraglutide, mild agitation or limited headspace produced little structural change, whereas more headspace with stronger agitation promoted fibrillation [6]. A jet of liquid onto the cake also traps air and wets it unevenly, which is when cakes float amid foam [3].
Checking the solution
Hold the vial against dark and light backgrounds. A correctly dissolved peptide is clear and colourless with no particles or strands. Shining a torch through the side shows faint haze that is otherwise easy to miss. Opalescence can mean self-association, and is a reason to investigate rather than to proceed; peptide aggregation covers the mechanisms.
Do not filter a cloudy solution to make it look clear. The filter removes the undissolved or aggregated peptide, and the concentration of what passes through is then unknown.
Concentration maths
Concentration (mg/mL) = peptide mass (mg) ÷ diluent volume (mL). The table covers common fills; check that the higher values are within the peptide's solubility.
| Peptide mass | 1.0 mL | 2.0 mL | 3.0 mL | 5.0 mL |
|---|---|---|---|---|
| 5 mg | 5.0 mg/mL | 2.5 mg/mL | 1.67 mg/mL | 1.0 mg/mL |
| 10 mg | 10 mg/mL | 5.0 mg/mL | 3.33 mg/mL | 2.0 mg/mL |
| 50 mg | 50 mg/mL | 25 mg/mL | 16.7 mg/mL | 10 mg/mL |
Molar concentration (mM) = concentration (mg/mL) ÷ molecular weight (g/mol) × 1,000. Because molecular weights differ several-fold, the same mass gives very different molarities:
| Peptide | Average MW (g/mol) | 5 mg in 2.0 mL | 10 mg in 2.0 mL |
|---|---|---|---|
| Epithalon (Ala-Glu-Asp-Gly) | 390.35 | 6.40 mM | 12.81 mM |
| Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) | 751.87 | 3.33 mM | 6.65 mM |
| BPC-157 (15 residues) | 1419.54 | 1.76 mM | 3.52 mM |
| MOTS-c (16 residues) | 2174.59 | 1.15 mM | 2.30 mM |
These figures treat the whole fill as peptide. If batch documentation gives a net peptide content of, say, 80%, multiply by 0.80: 10 mg of BPC-157 in 2.0 mL is then 2.82 mM, not 3.52 mM. Peptide molarity calculations works through the correction.
For working solutions, C1V1 = C2V2. To make 1 mL of 10 µM Selank from a 6.65 mM stock, V1 = (10 µM × 1,000 µL) ÷ 6,650 µM = 1.5 µL, too small to pipette reliably. An intermediate 1:100 dilution (66.5 µM) followed by 150 µL into 850 µL gives the same result with far less pipetting error. The reconstitution calculator and dilution calculator do this arithmetic.
Keep stocks concentrated
Peptides adsorb to container surfaces, and the fraction lost grows as concentration falls. Recovery of eight radiolabelled endocrine peptides from glass and plastic tubes differed widely by peptide and surface; siliconising the tubes reduced recovery, while 1% bovine serum albumin improved it [7]. Cetrorelix at 0.2–4 µg/mL lost enough to vial walls to make HPLC responses poor and variable, with adsorption ranked glass > polypropylene = polyethylene > PTFE and large differences between glass vials from different suppliers [4].
In practice: store stocks at mg/mL rather than µg/mL, dilute into assay buffer at the last step, use low-binding polypropylene for dilute solutions, add a carrier protein to assay buffers where the assay tolerates it, and check recovery when a low-concentration standard matters.
Aliquoting and freezing
Lyophilisation exists to give peptides and proteins a long-term stability that solutions lack [8], so a reconstituted stock should be divided rather than held in one vial. Freezing is itself a stress: in 100 mM sodium phosphate, selective crystallisation of the buffer salt dropped pH by about three units on cooling to −25 °C and aggregated two model proteins, and reducing the buffer to 10 mM prevented it [9]. Freeze peptide stocks in water or a low-strength buffer.
- Divide the stock into single-experiment aliquots in low-binding, screw-cap cryotubes with O-ring seals.
- Size each aliquot for one experiment plus a pipetting margin, so nothing is returned to the freezer.
- Freeze promptly at −20 °C or below; colder storage slows chemical degradation further. Avoid frost-free freezers, whose defrost cycles warm their contents.
- Thaw once, mix by gentle inversion, spin down briefly and discard what is left. Each additional freeze–thaw cycle adds exposure.
- For aggregation-prone sequences, aliquot the stock only after it has been made monomeric. Amyloid researchers treat synthetic peptide with a strong solvent first to erase the "structural history" that can seed aggregation [10].
A stock destined for single-use frozen aliquots gains nothing from a preservative, so sterile water is the simpler diluent there.
Labelling
Label every tube before it goes into the freezer, using cryo-rated labels or a solvent-resistant marker on the side of the tube rather than only the cap.
| Field | Example | Why it matters |
|---|---|---|
| Peptide and lot | BPC-157, lot as printed on the vial | Links the tube to its batch documentation |
| Concentration, mass and molar | 2.50 mg/mL (1.76 mM) | Avoids recalculating from memory |
| Net peptide content applied | "NPC not applied" or "NPC 0.80 applied" | Shows which concentration basis was used |
| Diluent and its lot | Sterile water, lot number | Defines the vehicle control |
| Date and initials | 2026-10-05, initials | Traceability |
| Aliquot number | A07 of 20 | Tracks use and freeze–thaw count |
Common errors
| Error | Consequence | Fix |
|---|---|---|
| Opening a cold vial | Condensation on powder and glass | Equilibrate sealed |
| Jetting diluent or vortexing | Foam and interfacial aggregation | Add down the wall, swirl |
| Treating fill mass as peptide mass | Molar concentration overstated | Apply net peptide content |
| Storing dilute working solutions | Adsorption losses | Store concentrated, dilute last |
| Freezing in 100 mM phosphate | pH shift on freezing | Water or low-strength buffer |
| Pipetting 1–2 µL volumes | Large relative error | Use an intermediate dilution |
| Unlabelled tubes | Unusable stock | Label before freezing |
Bench checklist
- Equilibrate the sealed vial to room temperature; collect the powder.
- Check molecular weight, salt form and net peptide content in the batch documentation.
- Choose the diluent from net charge, residue content and the assay.
- Add the diluent down the wall; swirl, roll and wait.
- Inspect for clarity; troubleshoot rather than shake.
- Calculate mass and molar concentrations and record the basis.
- Aliquot, label and freeze; log everything.
Frequently asked questions
How much diluent should go into a peptide vial?
There is no single correct volume. Work back from the stock concentration the experiment needs and check it is within the peptide's solubility: 2.0 mL in a 5 mg vial gives 2.5 mg/mL, 1.0 mL gives 5.0 mg/mL. Concentrated stocks lose proportionally less peptide to container walls [4]. The reconstitution calculator handles any vial size and volume, and the molarity calculator converts the result to mM.
Should a peptide vial be vortexed or shaken to dissolve it?
Not as a first step. Shear at bench intensity is not the problem; experiments on concentrated antibody solutions found shear alone caused no aggregation, whereas forces at the air–water interface are far larger [5]. Vigorous agitation creates foam and fresh interface, and for the peptide liraglutide, agitation with more headspace promoted fibrillation [6]. Gentle swirling, rolling and time dissolve most peptides.
Is bacteriostatic water or sterile water better for reconstitution?
It depends on how the stock will be used. Sterile water suits single-use aliquots and cell-based assays because it adds nothing to the vehicle. Bacteriostatic water, with 0.9% benzyl alcohol, suits a refrigerated stock that will be entered repeatedly for biochemical work. The trade-offs are set out in bacteriostatic water vs sterile water.
Why does a measured concentration come out lower than the calculated one?
Usually for one of three reasons. The powder is not 100% peptide, because counter-ions and water add mass, so net peptide content has to be applied. Peptide can also adsorb to glass and plastic, especially in dilute solutions [4, 7]. Finally, the dissolution may be incomplete. Peptide molarity calculations covers the corrections.
Can a reconstituted peptide stock be frozen and thawed more than once?
Avoid it. Drying is what gives these molecules long-term stability [8], and each freeze exposes the solution to ice interfaces and concentrating solutes; in 100 mM sodium phosphate, cooling shifted pH by about three units and aggregated model proteins [9]. Single-use aliquots mean each portion is thawed once.
References
- 1.Costantino HR, Langer R, Klibanov AM. Moisture-induced aggregation of lyophilized insulin. Pharm Res. 1994. PubMed 8140052
- 2.Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999. PubMed 10567002
- 3.Kulkarni SS, Patel SM, Suryanarayanan R, et al. Key factors governing the reconstitution time of high concentration lyophilized protein formulations. Eur J Pharm Biopharm. 2021. PubMed 33974974
- 4.Grohganz H, Rischer M, Brandl M. Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface. Eur J Pharm Sci. 2004. PubMed 14757490
- 5.Bee JS, Stevenson JL, Mehta B, et al. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng. 2009. PubMed 19370772
- 6.Hamada N, Cutts A, Song J, et al. Molecular Mechanisms of Liraglutide Aggregation Induced by Dual Air-Water and Silicone-Oil-Water Interfacial Stress. Mol Pharm. 2026. PubMed 41572471
- 7.Goebel-Stengel M, Stengel A, Taché Y, et al. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011. PubMed 21315060
- 8.Kasper JC, Friess W. The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur J Pharm Biopharm. 2011. PubMed 21426937
- 9.Thorat AA, Munjal B, Geders TW, et al. Freezing-induced protein aggregation - Role of pH shift and potential mitigation strategies. J Control Release. 2020. PubMed 32335158
- 10.Stine WB, Jungbauer L, Yu C, et al. Preparing synthetic Aβ in different aggregation states. Methods Mol Biol. 2011. PubMed 20967580
This article summarises published research for educational purposes. It is not medical advice. Compounds sold by Australian Peptide Lab are research reagents for in-vitro laboratory use only, not for human or veterinary use.
